Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46) - eBioMedicine
Clinical Trials - Cue Biopharma
Innovative design for a phase 1 trial with intra-patient dose escalation: The Crotoxin study | Semantic Scholar
A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method | BMC Cancer | Full Text
On Biostatistics and Clinical Trials: Phase I Dose Escalation Study Design: "3 + 3 Design"
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial - The Lancet
Sequential dose-escalation study design | Download Scientific Diagram
Dose-finding trials: why not to use algorithmic designs
exv99w1
The 3 + 3 dose escalation study design. DLT, dose limiting toxicity;... | Download Scientific Diagram
The Classic 3 + 3 Design in Dose-finding Clinical Trials and Its Alternatives | Genpro Research
Flexibility of the BLRM in Dose-Escalation Trials
توییتر \ Stephen V Liu, MD در توییتر: «#OncoAlert #AACR20 Dose escalation of TAK-788 (mobocertinib) established MTD of 160mg qday. DLTs were 1 case each of grade 3 diarrhea, grade 3 mucositis,
5 Reasons to Invest in Bayesian Dose-Escalation Methods
Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era - ScienceDirect
Early phase clinical trials to identify optimal dosing and safety - ScienceDirect
Dose intra‐subject escalation to an event (DIETE): A new method for phase 1 dose‐finding utilizing systematic intra‐subject dose escalation with application to T‐cell engagers - Xu - 2021 - Pharmaceutical Statistics -
Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era - European Journal of Cancer
Figure 1 | Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors | SpringerLink
Ustekinumab dose escalation: An option for nonresponsive Crohn's? | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
Innovative design for a phase 1 trial with intra-patient dose escalation: The Crotoxin study - ScienceDirect
Protocol B7861002 A PHASE 1 DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVENOUS P
Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study
Cancers | Free Full-Text | Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy
